You are here

Home » Content

Refrakter Akut Humoral Renal Allograft Rejeksiyonunun Tek Doz Rituximab ile Başarılı Tedavisi

Successful Treatment of Refractory Acute Humoral Allograft Rejection with Single Dose Rituximab

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2010
DOI: 
doi: 10.5262/tndt.2010.1002.73

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Acute humoral rejection (AHR) is a rare event; however it can potentially lead to graft loss in up 40% of cases after 1 year of transplantation. A number of features like re-transplantation, ABO incompatibility and positive lymphocyte cross-match portend a high risk for AHR. We performed a retransplantation to a 23-year-old female patient who had lost her fi rst allograft due to polyomavirus nephropathy. After the second transplantation, she developed AHR that was confi rmed by allograft biopsy. We instituted steroid pulses for three days, alternate-day thymoglobulin, plasmapheresis and intravenous immunoglobulin. Despite this therapy, renal function did not improve; therefore as a last resort we administered singledose rituximab. Later on the course her urine output increased and kidney function recovered. In conclusion, rituximab can be tried as a last line of therapy in refractory AHR episodes.
Bookmark/Search this post with
Abstract (Original Language): 
Akut humoral rejeksiyon (AHR) nadir bir olaydır, ancak transplantasyondan 1 yıl sonrasında greft kayıplarının %40’ı kadarından sorumlu olabilir. Tekrarlayan transplantasyon, ABO kan grubu uyumsuzluğu ve pozitif lenfosit cross-match gibi bazı özellikler AHR için yüksek risk teşkil eder. İlk transplant böbreğini poliomavirüs enfeksiyonu nedeniyle kaybeden 23 yaşındaki kadın hastaya ikinci böbrek naklini yapıldı. Hastada nakil sonrası, böbrek biyopsisi ile konfi rme edilen AHR gelişti. Üç gün boyunca günlük pulse steroid, günaşırı timoglobulin ve plazmaferez uygulandı. Daha sonra IVIG verildi. Bu tedavilere rağmen böbrek fonksiyonları iyileşmedi. Son çare olarak hastaya tek doz rituximab uyguladık verildi. Hastanın idrar çıkışı ve fonksiyonları iyileşti. Sonuç olarak, refrakter AHR episodlarında rituximab son tedavi seçeneği olarak denenebilir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_19_pp_140-142.pdf
  • 2
140-142
  • Turkish

REFERENCES

References: 

1. Bock HA: Steroid-resistant kidney transplant rejection: Diagnosis
and treatment. J Am Soc Nephrol 2001; 12 Suppl 17:48-52
2. Rai KR: Future strategies toward the cure of indolent B-cell
malignancies. New biologic therapies. Semin Hematol. 1999;
36:12-17 Review. Erratum in: Semin Hematol 2000; 37(2):217
3. Becker Y, Becker B, Knechtle S: Transplantation of steroid
resistant rejection with a novel anti B-cell preparation Rituximab.
Transplantation 2000; 69:362
4. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A,
Mari A, Ribes D, Cointault O, Lavayssière L, Guitard J, Durand
D, Rostaing L: Rituximab therapy for acute humoral rejection after
kidney transplantation. Transplantation 2007; 83(9):1277-1280
5. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King
KE, Burdick J, Maley WR, Ratner LE: Plasmapheresis and
intravenous immune globulin provides effective rescue therapy for
refractory humoral rejection and allows kidneys to be successfully
transplanted into cross-match-positive recipients. Transplantation
2000; 70(6):887-895
6. Becker YT, Becker BN, Pirsch JD, Sollinger HW: Rituximab as
treatment for refractory kidney transplant rejection. Am J Transplant
2004; 4(6):996-1001
7. Grillo-Lopez AJ: Rituximab: An insider’s historical perspective.
Semin Oncol 2000; 27:9-16
8. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek
M, Salvatierra O Jr: Molecular heterogeneity in acute renal allograft
rejection identifi ed by DNA microarray profi ling. N Engl J Med
2003; 349(2):125-138

Thank you for copying data from http://www.arastirmax.com